Abstract
Background: Neonatal sepsis (NS) remains one of the leading causes of mortality among newborns. This study found the deregulated microRNA-96 (miR-96) in NS neonates, and aimed to evaluate the clinical significance of miR-96, as well as its effect on LPS-induced inflammatory response in monocytes. In addition, the relationship of interleukin-16 (IL-16) and miR-96 was investigated to understand the underlying mechanisms.
Methods: Expression of miR-96 was examined using real-time quantitative PCR. Monocytes stimulated by LPS was used to mimic excessive inflammation in the pathogenesis of NS. The enzyme-linked immunosorbent assay was applied to evaluate pro-inflammatory cytokine levels. A luciferase reporter assay was used to confirm the interaction between miR-96 and IL-16.
Results: Serum miR-96 expression was decreased in NS newborns and had considerable diagnostic value for NS screening. LPS inhibited miR-96 expression in monocytes, and the overexpression of miR-96 could reverse the effects of LPS on the inflammation of monocytes. IL-16 was a target gene of miR-96 and negatively correlated with miR-96 levels in NS neonates. The inhibited inflammatory responses induced by miR-96 overexpression was abolished by the elevated IL-16 in monocytes.
Conclusion: All the data reveal that serum decreased miR-96 may serve as a candidate noninvasive biomarker for NS diagnosis. In addition, miR-96 inhibits LPS-induced inflammatory responses by targeting IL-16 in monocytes. The miR-96/IL-16 axis may provide novel therapeutic targets for NS treatment.
Keywords: MicroRNA-96, neonatal sepsis, diagnosis, inflammation, monocyte, interleukin-16.
Graphical Abstract
[http://dx.doi.org/10.1007/s12325-017-0622-8] [PMID: 29022217]
[http://dx.doi.org/10.1016/S0140-6736(17)31002-4] [PMID: 28434651]
[http://dx.doi.org/10.1016/j.biopha.2018.08.064] [PMID: 30223098]
[http://dx.doi.org/10.1097/MOP.0000000000000315] [PMID: 26766602]
[http://dx.doi.org/10.1007/s00101-017-0363-8] [PMID: 28980026]
[http://dx.doi.org/10.1080/14767058.2017.1322060] [PMID: 28427289]
[http://dx.doi.org/10.3389/fphar.2020.00109] [PMID: 32153412]
[http://dx.doi.org/10.1016/j.cyto.2016.03.017] [PMID: 27031442]
[http://dx.doi.org/10.1016/j.peptides.2015.06.009] [PMID: 26206287]
[http://dx.doi.org/10.1016/j.mcp.2020.101573] [PMID: 32325105]
[http://dx.doi.org/10.2147/OTT.S239887] [PMID: 32308426]
[http://dx.doi.org/10.1111/1759-7714.13428] [PMID: 32301290]
[http://dx.doi.org/10.1111/febs.14482] [PMID: 29688631]
[http://dx.doi.org/10.1155/2019/5306541] [PMID: 31780861]
[http://dx.doi.org/10.3892/ol.2018.9308] [PMID: 30250569]
[http://dx.doi.org/10.1007/s10875-014-0004-9] [PMID: 24668300]
[PMID: 14723808]
[http://dx.doi.org/10.1002/eji.200526258] [PMID: 16285008]
[http://dx.doi.org/10.1016/j.yexcr.2018.05.002] [PMID: 29730164]
[http://dx.doi.org/10.1186/s13052-019-0655-5] [PMID: 31088519]
[http://dx.doi.org/10.1074/jbc.M113.492496] [PMID: 24092752]
[http://dx.doi.org/10.1016/j.biopha.2016.11.147] [PMID: 28006751]
[PMID: 31938374]
[http://dx.doi.org/10.3390/ijms17010078] [PMID: 26761003]
[PMID: 26131152]
[http://dx.doi.org/10.3892/ol.2019.10606] [PMID: 31452818]
[http://dx.doi.org/10.1007/s12022-017-9504-5] [PMID: 29032398]
[http://dx.doi.org/10.1038/pr.2017.41] [PMID: 28288151]
[http://dx.doi.org/10.1046/j.1365-2567.2000.00997.x] [PMID: 10809960]
[http://dx.doi.org/10.1016/j.molimm.2018.12.027] [PMID: 30634164]